

MedLife has successfully signed a new increase by EUR 50 million of its syndicated loan, up to a total amount of approximately EUR 185 million: "The new funds will be allocated to consolidate the position at national level, increase the presence at regional level and amplify the research division projects"

- *M&A and the expansion of the medical infrastructure remain a priority, with MedLife having another 2-3 advanced discussions at national level and 1-2 at regional level.*
- *The company will consolidate its efforts in the research area as well, and will invest 3-5 million in one of the most modern laboratories with a high degree of biosecurity in the field of virology, genetics and molecular biology in Romania.*
- *The new funds will also be used for the development of regional hospitals, by expanding existing units, related infrastructure in the area of oncology and post-COVID programs.*
- *After reaching the threshold of a quarter of a billion euros last year in terms of turnover, MedLife is set to become the first private medical company in Romania to reach one third of a billion euros this year.*

Bucharest, December 7, 2021: MedLife Medical System, the leader of the Romanian private medical services market, announces the signing of the increase of the existing syndicated loan with the amount of EUR 50 million, up to a total value of EUR 185 million, together with other amendments. The funds will be allocated to strengthen the position at national level, increase the presence at regional level, as well as amplify the research projects carried out by the company.

The M&A and development plan at group-level is a constant priority for MedLife. This year, the company focused, especially, on acquisitions in the oncology diagnostic and treatment services area, MedLife recently signing the acquisition of two reference centers in this field, Neolife Medical Center and OncoCard Braşov. The group aims to strengthen locally, by developing regional hospitals where the patient benefits from a 360-degree approach both in terms of the complexity of the medical act and the quality of related services, but also by expanding the medical infrastructure. In addition, the growth ambitions are aimed at consolidating the presence in the international market, MedLife already being present on the Hungarian market since 2019. Another priority is the continuation of research division, which has an important role in monitoring the pandemic, the company conducting numerous studies exclusively with own resources.

The syndicate of banks which signs the new syndicated loan granted to MedLife consists of Banca Comerciala Romana, as coordinator, mandated lead arranger, documentation agent, facility & security agent and lender, Raiffeisen Bank, BRD Groupe Societe Generale and Banca Transilvania, as lead arrangers and lenders.

"This year has brought us new opportunities for business development, and the results obtained until now are a confirmation of our efforts. By continuing our local acquisitions, we have consolidated our leading position, including in the area of oncology and radiotherapy, managing to provide patients with integrated medical services for the diagnosis and treatment of oncological pathology. With this new funding, we are pursuing new strategic goals, both at the local level, where for the next period we intend to carry out important new M&A transactions, but also at the regional level, where we analyze and look for the most efficient solutions to bring our model in other European countries" said Mihai Marcu, President and CEO of MedLife Group.

"Ambitious plans need constant support, while Romanian businesses need such sustainable examples. It is the second syndicated loan signed by MedLife group this year and we are proud to support business development, thus contributing to increasing the quality of medical services in Romania", said Oana Macoveiciuc, Head of Consumer Products and Services BCR. *"Syndicated financing is the right solution*

for Romanian entrepreneurial companies that aim to diversify income sources and grow on solid grounds. MedLife Group has become the largest provider of medical services with an integrated expansion strategy and we are glad that we have developed a long-term partnership through these syndicated financing", added Grația Popescu, Senior Banker Loan Syndication BCR.

MedLife closed the first 9 months of this year with a pro-forma consolidated turnover of 1.2 billion lei, up by 56.5% compared to the same period last year. Financial outlooks for the year end are more than optimistic, and MedLife has the chance to become the first private medical company in Romania to reach one third of a billion euros turnover this year.

About MedLife Medical System:

MedLife Medical System started 26 years ago, has developed healthily and has become the largest provider of private medical services in Romania. Romanian entrepreneurs, who founded this company, invested and got involved to change the Romanian health system, believed in innovation and dared to aim as high as possible, to offer Romanian patients qualitative services, professionalism, care and respect for their needs.

The company operates the largest network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals and has the largest corporate clients base for Health Prevention Packages in the country. It is also one of the largest private healthcare providers in Central and Eastern Europe in terms of sales.

MedLife Group has a history of success in terms of both organic growth and by acquisitions. Strong and experienced management team, was able to create and manage these growth opportunities, gaining valuable knowledge and experience, which allows to find the best way to successfully continue the expansion.

Being a Romanian company with a tradition, MedLife chose to be listed on the Romanian Stock Exchange, being a model for listings on the local capital market. It has opened up new horizons, and through the corporate governance it has implemented, has inspired other local companies to embark on this path and help develop the Romanian capital and economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, with the trading symbol " M ".

During the pandemic, MedLife managed to play a key role in society and gain a detached leadership status in pandemic monitoring through active involvement in research activities. The company continues to invest in projects in technology and infrastructure, with impact on the local community. It creates jobs and develops an ecosystem that contributes to the development and maintenance of a healthy Romania.